Literature DB >> 17219202

Effect of lycopene on insulin-like growth factor-I, IGF binding protein-3 and IGF type-I receptor in prostate cancer cells.

P Kanagaraj1, M R Vijayababu, B Ravisankar, J Anbalagan, M M Aruldhas, J Arunakaran.   

Abstract

PURPOSE: Prostate cancer is the second most common cancer that leads to death in elderly men. The risk of prostate cancer prevalence is often associated with the elevated level of insulin-like growth factor-I (IGF-I) and decreased level of IGF-binding protein 3 (IGFBP-3). Lycopene, a carotenoid, reduces the proliferation of cancer cells and induces apoptosis. Hence, higher intake of lycopene can be associated with the lower risk of prostate cancer. However, the mechanism of action of lycopene in the prevention of prostate cancer is still unclear. The present study was carried out to study the effects of lycopene on the components of IGF system and apoptosis in androgen-independent prostate cancer cells (PC-3 cells).
METHODS: PC-3 cells were treated with various concentrations of lycopene, (20, 40 and 60 microM) for 24, 48, 72 and 96 h. IGF-I, IGFBP-3 and IGF-I receptor (IGF-IR) levels in lycopene-treated cells were evaluated. Annexin V and propidium iodide (PI) binding studies were done to assess apoptosis.
RESULTS: PC-3 cells treated with lycopene showed a significant decrease in cell proliferation. Lycopene, at a dose of 40 microM, significantly increased the level of IGFBP-3. Lycopene-induced apoptosis was confirmed by annexin V and PI binding. Lycopene-induced DNA fragmentation was absent after 24 h treatment whereas the same was observed after 48 h treatment. There was a significant decrease in the IGF-IR expression after the cells were treated with lycopene and IGF-I.
CONCLUSION: The data obtained suggest that the components of the IGF system may act as a positive regulator of lycopene-induced apoptosis in PC-3 cells. Thus, the observed lycopene-induced biological effects and their associated mechanisms are encouraging and may lead to the development of a highly successful drug for the treatment of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17219202     DOI: 10.1007/s00432-006-0177-6

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.322


  40 in total

1.  Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell lines.

Authors:  Ju Zhang; Klaus Jung; Michael Lein; Glen Kristiansen; Birgit Rudolph; Steffen Hauptmann; Dietmar Schnorr; Stefan A Loening; Ralf Lichtinghagen
Journal:  Prostate       Date:  2002-01-01       Impact factor: 4.104

Review 2.  Octreotide in the management of hormone-refractory prostate cancer.

Authors:  I G Vainas
Journal:  Chemotherapy       Date:  2001       Impact factor: 2.544

3.  The effect of lycopene on cell growth and oxidative DNA damage of Hep3B human hepatoma cells.

Authors:  Yun Ok Park; Eun-Sun Hwang; Tae Wha Moon
Journal:  Biofactors       Date:  2005       Impact factor: 6.113

Review 4.  The potential role of lycopene for human health.

Authors:  H Gerster
Journal:  J Am Coll Nutr       Date:  1997-04       Impact factor: 3.169

Review 5.  The management of hormone refractory prostate cancer.

Authors:  D W Newling
Journal:  Eur Urol       Date:  1996       Impact factor: 20.096

6.  Physiologically attainable concentrations of lycopene induce mitochondrial apoptosis in LNCaP human prostate cancer cells.

Authors:  Holly L Hantz; Leeanne F Young; Keith R Martin
Journal:  Exp Biol Med (Maywood)       Date:  2005-03

7.  Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines.

Authors:  M Iwamura; P M Sluss; J B Casamento; A T Cockett
Journal:  Prostate       Date:  1993       Impact factor: 4.104

8.  Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089.

Authors:  H Huynh; M Pollak; J C Zhang
Journal:  Int J Oncol       Date:  1998-07       Impact factor: 5.650

9.  Establishment and characterization of a human prostatic carcinoma cell line (PC-3).

Authors:  M E Kaighn; K S Narayan; Y Ohnuki; J F Lechner; L W Jones
Journal:  Invest Urol       Date:  1979-07

10.  Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis.

Authors:  G Koopman; C P Reutelingsperger; G A Kuijten; R M Keehnen; S T Pals; M H van Oers
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

View more
  13 in total

Review 1.  Diet and prostate cancer: mechanisms of action and implications for chemoprevention.

Authors:  Vasundara Venkateswaran; Laurence H Klotz
Journal:  Nat Rev Urol       Date:  2010-07-20       Impact factor: 14.432

2.  Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004.

Authors:  Katharina Nimptsch; Elizabeth A Platz; Michael N Pollak; Stacey A Kenfield; Meir J Stampfer; Walter C Willett; Edward Giovannucci
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

Review 3.  Multitargeted therapy of cancer by lycopene.

Authors:  Richard B van Breemen; Natasa Pajkovic
Journal:  Cancer Lett       Date:  2008-06-27       Impact factor: 8.679

Review 4.  Bioactivities of phytochemicals present in tomato.

Authors:  Poonam Chaudhary; Ashita Sharma; Balwinder Singh; Avinash Kaur Nagpal
Journal:  J Food Sci Technol       Date:  2018-06-01       Impact factor: 2.701

5.  Chemoprevention of prostate cancer with lycopene in the TRAMP model.

Authors:  Ramdev Konijeti; Susanne Henning; Aune Moro; Ahmed Sheikh; David Elashoff; Ari Shapiro; Melvin Ku; Jonathan W Said; David Heber; Pinchas Cohen; William J Aronson
Journal:  Prostate       Date:  2010-10-01       Impact factor: 4.104

Review 6.  Tomato-based food products for prostate cancer prevention: what have we learned?

Authors:  Hsueh-Li Tan; Jennifer M Thomas-Ahner; Elizabeth M Grainger; Lei Wan; David M Francis; Steven J Schwartz; John W Erdman; Steven K Clinton
Journal:  Cancer Metastasis Rev       Date:  2010-09       Impact factor: 9.264

7.  Low expression of ERK signaling pathway affecting proliferation, cell cycle arrest and apoptosis of human gastric HGC-27 cells line.

Authors:  BeiLi Zhang; Yan Gu
Journal:  Mol Biol Rep       Date:  2014-02-20       Impact factor: 2.316

Review 8.  Tomatoes, Lycopene, and Prostate Cancer: What Have We Learned from Experimental Models?

Authors:  Nancy E Moran; Jennifer M Thomas-Ahner; Lei Wan; Krystle E Zuniga; John W Erdman; Steven K Clinton
Journal:  J Nutr       Date:  2022-06-09       Impact factor: 4.687

Review 9.  The potential role of lycopene for the prevention and therapy of prostate cancer: from molecular mechanisms to clinical evidence.

Authors:  Nina Pauline Holzapfel; Boris Michael Holzapfel; Simon Champ; Jesper Feldthusen; Judith Clements; Dietmar Werner Hutmacher
Journal:  Int J Mol Sci       Date:  2013-07-12       Impact factor: 5.923

Review 10.  Watermelon lycopene and allied health claims.

Authors:  Ambreen Naz; Masood Sadiq Butt; Muhammad Tauseef Sultan; Mir Muhammad Nasir Qayyum; Rai Shahid Niaz
Journal:  EXCLI J       Date:  2014-06-03       Impact factor: 4.068

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.